alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 502 studies published 2020 · free to read (page 6 of 21) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Alzheimer's research & therapy 2020-01-07

Insomnia in cognitively unimpaired adults at increased risk for AD is associated to poorer performance in some executive functions and volume changes in cortical and subcortical gray matter, including key areas involved in Alzheimer's disease, as well as decreased white matter diffusivity. 4 key findings →

Design: cross-sectional Participants: 366 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Nature communications 2020-02-03

Each additional copy of the apolipoprotein E4 (APOE4) allele is associated with a higher risk of Alzheimer's dementia, while the APOE2 allele is associated with a lower risk of Alzheimer's dementia, it is not yet known whether APOE2 homozygotes have a particularly low risk. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Nature 2020-02-05

Synucleinopathies are neurodegenerative diseases that are associated with the misfolding and aggregation of α-synuclein, including Parkinson's disease, dementia with Lewy bodies and multiple system atrophy 1 . 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evidence for Environmental Noise Effects on Health for the United Kingdom Policy Context: A Systematic Review of the Effects of Environmental Noise on Mental Health, Wellbeing, Quality of Life, Cancer, Dementia, Birth, Reproductive Outcomes, and Cognition

✓ Peer-reviewed alzhub usefulness score 61 out of 100. International journal of environmental research and public health 2020-01-07

This systematic review commissioned by the UK Department for the Environment, Food and Rural Affairs (Defra), considers how the evidence base for noise effects on health has changed following the recent reviews undertaken for the WHO Environmental Noise Guidelines. 5 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort

✓ Peer-reviewed alzhub usefulness score 61 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 2020-10-01

There are specific high-risk preexisting comorbidities for COVID-19 hospitalization and related deaths in community-based older men and women. 3 key findings →

Participants: 19 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Microstructural disruption of the right inferior fronto-occipital and inferior longitudinal fasciculus contributes to WMH-related cognitive impairment

✓ Peer-reviewed alzhub usefulness score 61 out of 100. CNS neuroscience & therapeutics 2020-01-04

Changes in the properties of DTI may be the potential mechanism of WMH-related MCI, especially the right IFOF and the right ILF, which may become imaging markers for predicting WMH-related cognitive dysfunction. 2 key findings →

Design: longitudinal study Participants: 22 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Neurology 2020-09-28

At baseline, participants (n = 168) were cognitively normal and primarily middle-aged (mean 56.4 years, SD 10.9 years) and had both vascular risk factor status and proximal CSF biomarkers available. 4 key findings →

Design: cohort study Participants: 168 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2020-09-28

Alzheimer disease pathologic changes are common in DLB and are associated with the clinical phenotype. β-Amyloid is associated with cognitive impairment, and tau pathology is associated with lower frequency of clinical features of DLB. 5 key findings →

Participants: 417 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA neurology 2020-07-01

The genotype KL-VSHET+ is associated with reduced AD risk and Aβ burden in individuals who are aged 60 to 80 years, cognitively normal, and carrying APOE4. 5 key findings →

Design: case-control study Participants: 20 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Danggui-Shaoyao-San for dementia: A PRISMA-compliant systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Medicine 2020-01-01

These estimates suggest that DSS provides clinically important reductions in symptoms of AD and VD and can be a promising anti-dementia drug candidate. 5 key findings →

Design: systematic review Participants: 567 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The impact of a multi-domain intervention on cerebral glucose metabolism: analysis from the randomized ancillary FDG PET MAPT trial

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's research & therapy 2020-10-19

MI failed to show an effect on metabolism in FDG-based AD biomarker, but exploratory analysis suggested positive effect on limbic system metabolism. 4 key findings →

Participants: 67 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 60 out of 100. The Lancet. Public health 2020-12-01

Overall age-adjusted and sex-adjusted prevalence was estimated to be 6·0% (95% CI 5·8-6·3) for dementia, 3·9% (3·8-4·1) for Alzheimer's disease, 1·6% (1·5-1·7) for vascular dementia, and 0·5% (0·5-0·6) for other dementias. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A systematic literature review of automatic Alzheimer's disease detection from speech and language

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of the American Medical Informatics Association : JAMIA 2020-11-01

The systematic literature review supported the argument that language and speech could successfully be used to detect dementia automatically. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The effect of digital reminiscence therapy on people with dementia: a pilot randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 60 out of 100. BMC geriatrics 2020-05-06

Digital RT proved an innovative approach to manage PWD and will thus help PWD achieve a better mood and have more opportunities to engage in social interactions. 3 key findings →

Participants: 25 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of amyloid-β CSF/PET discordance and tau load 5 years later

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2020-09-10

We included 730 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants without dementia (282 cognitively normal, 448 mild cognitive impairment) with baseline [ 18 F]florbetapir PET and CSF Aβ 42 available. 4 key findings →

Design: longitudinal study Participants: 318 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA network open 2020-10-01

Several clinical trials are planned for familial forms of frontotemporal lobar degeneration (f-FTLD). 4 key findings →

Design: case-control study Participants: 100 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Scientific reports 2020-06-08

Cerebrospinal fluid (CSF) biomarkers are useful in the diagnosis and the prediction of progression of several neurodegenerative diseases. 2 key findings →

Participants: 535 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events